Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard B Kim

Showing results (41-50 of 226) with videos related to

Pageof 23
Sort By:
Pharmacogenomics|April 23, 2004
Pharmacogenomics of the OATP and OAT familiesCatia Marzolini, Rommel G Tirona, Richard B Kim
The Canadian Journal of Cardiology|February 10, 2015
The impact of obesity on the pharmacology of medications used for cardiovascular risk factor controlSowndramalingam Sankaralingam, Richard B Kim, Raj S Padwal
Pharmacogenetics and Genomics|December 16, 2025
NFIB rs28379954 does not affect CYP2D6-mediated metabolism of prototypical substrates, tamoxifen or solanidineSamantha Medwid, Ute I Schwarz, Richard B Kim
Current Drug Metabolism|August 17, 2005
Beyond CAR and PXRSantosh G Dixit, Rommel G Tirona, Richard B Kim
Basic & Clinical Pharmacology & Toxicology|September 11, 2012
Absence of both MDR1 (ABCB1) and breast cancer resistance protein (ABCG2) transporters significantly alters rivaroxaban disposition and central nervous system entryInna Y Gong, Sara E Mansell, Richard B Kim
Drug Metabolism and Disposition: the Biological Fate of Chemicals|December 15, 2010
Endoxifen, the active metabolite of tamoxifen, is a substrate of the efflux transporter P-glycoprotein (multidrug resistance 1)Wendy A Teft, Sara E Mansell, Richard B Kim
BMC Cancer|May 13, 2016
Profound reduction in tamoxifen active metabolite endoxifen in a breast cancer patient treated with rifampin prior to initiation of an anti-TNFα biologic for ulcerative colitis: a case reportSara L Henderson, Wendy A Teft, Richard B Kim
Molecular Cancer Therapeutics|July 29, 2003
Pharmacogenetics of ATP-binding cassette transporters in cancer and chemotherapyA Craig Lockhart, Rommel G Tirona, Richard B Kim
Journal of Clinical Pharmacology|April 20, 2007
Nuclear receptors and the regulation of drug-metabolizing enzymes and drug transporters: implications for interindividual variability in response to drugsBradley L Urquhart, Rommel G Tirona, Richard B Kim
Clinical Pharmacology and Therapeutics|March 1, 2005
Effect of grapefruit juice volume on the reduction of fexofenadine bioavailability: possible role of organic anion transporting polypeptidesGeorge K Dresser, Richard B Kim, David G Bailey
Pageof 23

Showing results (41-50 of 226) with videos related to

Sort By:
Pageof 23
Pharmacogenomics|April 23, 2004
Pharmacogenomics of the OATP and OAT familiesCatia Marzolini, Rommel G Tirona, Richard B Kim
The Canadian Journal of Cardiology|February 10, 2015
The impact of obesity on the pharmacology of medications used for cardiovascular risk factor controlSowndramalingam Sankaralingam, Richard B Kim, Raj S Padwal
Pharmacogenetics and Genomics|December 16, 2025
NFIB rs28379954 does not affect CYP2D6-mediated metabolism of prototypical substrates, tamoxifen or solanidineSamantha Medwid, Ute I Schwarz, Richard B Kim
Current Drug Metabolism|August 17, 2005
Beyond CAR and PXRSantosh G Dixit, Rommel G Tirona, Richard B Kim
Basic & Clinical Pharmacology & Toxicology|September 11, 2012
Absence of both MDR1 (ABCB1) and breast cancer resistance protein (ABCG2) transporters significantly alters rivaroxaban disposition and central nervous system entryInna Y Gong, Sara E Mansell, Richard B Kim
Drug Metabolism and Disposition: the Biological Fate of Chemicals|December 15, 2010
Endoxifen, the active metabolite of tamoxifen, is a substrate of the efflux transporter P-glycoprotein (multidrug resistance 1)Wendy A Teft, Sara E Mansell, Richard B Kim
BMC Cancer|May 13, 2016
Profound reduction in tamoxifen active metabolite endoxifen in a breast cancer patient treated with rifampin prior to initiation of an anti-TNFα biologic for ulcerative colitis: a case reportSara L Henderson, Wendy A Teft, Richard B Kim
Molecular Cancer Therapeutics|July 29, 2003
Pharmacogenetics of ATP-binding cassette transporters in cancer and chemotherapyA Craig Lockhart, Rommel G Tirona, Richard B Kim
Journal of Clinical Pharmacology|April 20, 2007
Nuclear receptors and the regulation of drug-metabolizing enzymes and drug transporters: implications for interindividual variability in response to drugsBradley L Urquhart, Rommel G Tirona, Richard B Kim
Clinical Pharmacology and Therapeutics|March 1, 2005
Effect of grapefruit juice volume on the reduction of fexofenadine bioavailability: possible role of organic anion transporting polypeptidesGeorge K Dresser, Richard B Kim, David G Bailey
Pageof 23